Navigation Links
New RNA-based therapeutic strategies for controlling gene expression
Date:2/2/2012

New Rochelle, NY, February 2, 2012Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity. A comprehensive review article in Nucleic Acid Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc., details these advances.

Short strands of nucleic acids, called small RNAs, can be used for targeted gene silencing, making them attractive drug candidates. These small RNAs block gene expression through multiple RNA interference (RNAi) pathways, including two newly discovered pathways in which small RNAs bind to Argonaute proteins or other forms of RNA present in the cell nucleus, such as long non-coding RNAs and pre-mRNA.

Keith T. Gagnon, PhD, and David R. Corey, PhD, University of Texas Southwestern Medical Center, in Dallas, review common features shared by RNAi pathways for controlling gene expression and focus in detail on the potential for Argonaute-RNA complexes in gene regulation and other exciting new options for targeting emerging forms of non-coding RNAs and pre-mRNAs in the article "Argonaute and the Nuclear RNAs: New Pathways for RNA Mediated Control of Gene Expression."

"The field of RNA mediated control of gene expression is rapidly evolving and the article by Gagnon and Corey provides a highly informative and up to date review of this exciting and often surprising area of biomedical research. We are delighted to publish this important review for the field," says Co-Editor-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Cell Therapeutics, Inc. Expects That the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February
2. New smart nanotherapeutics can deliver drugs directly to the pancreas
3. ISG15: A novel therapeutic target to slow breast cancer cell motility
4. Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference
5. New potential therapeutic target identified for Diffuse Large B-Cell Lymphoma
6. Discovery of therapeutic peptides affecting mitochondria
7. Lung stem cells offer therapeutic clues
8. Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
9. CHEO scientist advances biotherapeutics as published in Cancer Cell
10. Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity
11. Novel drug combination offers therapeutic promise for hard-to-treat cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New RNA-based therapeutic strategies for controlling gene expression
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... it has filed provisional patent 62/198989 for ... invention highlights a method to advance crypto-currencies such as ... introducing a common, uniform way to manage all payments.  ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... C (4.3 F) above pre-industrial levels even under extremely ... efforts to clean up particulate pollution continue to be ... of researchers at Scripps Institution of Oceanography at UC ... what the world,s leading climate change authority recently set ...
... By coupling a kicked-up version of microscopy with miniscule particles ... so deep into living tissue that they can see molecules ... the researchers believe that their new approach can have a ... a tumor as it is removed from the body to ...
... Cambridge, UK Any way you slice it, the ... , The planarian, a flatworm normally living in freshwater, ... a single planarian cut into 200 pieces can generate 200 ... not merely a fascinating master of regeneration, but can help ...
Cached Biology News:Warming world in range of dangerous consequences 2Warming world in range of dangerous consequences 3New technique sees into tissue at greater depth, resolution 2New technique sees into tissue at greater depth, resolution 3
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... WARRINGTON, Pa. , July 30, 2015 /PRNewswire/ ... announced that it has received the second $1.0M ... Business Innovation Research (SBIR) grant valued at up ... the company,s aerosolized KL4 surfactant as a potential ... lung injury.  Discovery Labs was awarded an initial ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... LOUIS, June 10 KV Pharmaceutical Company,(NYSE: ... that,develops, manufactures, acquires and markets technology-differentiated,branded products ... has become aware of litigation filed by ... challenging the patent rights,associated with PrimaCare ONE(R), ...
... pipeline of biologics ... disease and cancer, CAMBRIDGE, Mass., June 10 Merrimack ... of,novel treatments for autoimmune disease and cancer, today announced that ... financing., Existing and new investors participated in the financing ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... Phase 1/2 clinical trial for patients with,metastatic ... concurrent,intravenous (IV) and intraperitoneal (IP) administration of ... The National,Cancer Institute (NCI), part of the ...
Cached Biology Technology:KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business 2KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business 3Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R) 2Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R) 3
... Block MBS Start up kit. Includes configured ... choice of 2 MultiBlock satellite thermal ... blocks. User friendly software. Store/track ... height heated lid. Outstanding uniformity. ...
Glycerokinase; from Bacillus stearothermophilus...
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: